Behavioral Convulsions Faded With Repeated THC in a Sensitive Rabbit Population

A 1976 report described behavioral convulsions after low intravenous cannabinoid doses in a particular rabbit population. The observed events became less severe and disappeared during prolonged THC exposure.

The sensitivity was population-specific

The report concerned New Zealand White rabbits identified as unusually sensitive to stimulant-like cannabinoid effects. It did not establish that all rabbits or all species respond similarly. A selected animal population can be useful for mechanistic research while limiting generalization.

The endpoint was explicitly behavioral

The abstract describes convulsive behavior rather than providing an EEG-based seizure characterization. The observation should not be silently relabeled as a confirmed electrographic epilepsy model. Likewise, low dose is a description within the rabbit protocol, not a human exposure or safety category.

Adaptation does not establish benefit from continued exposure

The fading of events is consistent with tolerance to the measured response. It does not demonstrate an antiepileptic treatment, absence of other persistent effects or safety of escalating exposure. The authors proposed the population as a research model, rather than reporting clinical outcomes.

The report supports a narrow historical observation of sensitivity and adaptation. It cannot determine whether cannabis provokes or prevents seizures in an individual person. Species, selected population, intravenous route and the distinction between behavioral events and electrical confirmation are necessary parts of its interpretation.

Related: interpreting cannabis tolerance claims.

Research cited

Martin P; Consroe P. Cannabinoid induced behavioral convulsions in rabbits. Science (New York, N.Y.) (1976). doi:10.1126/science.982057. Findings discussed from the study abstract.

Spread the love


The National Black Lawyers

top 40 lawyers

civil trial law

Lawyers of Distinction

Loading...

Recent Blog Articles

A Psychiatric CBD Review’s Recommendation Grades Included Both CBD and THC-Containing Nabiximols

A review published in 2020 graded psychiatric evidence from studies of CBD and CBD-containing nabiximols. Its recommendation labels should not be quoted as though every underlying intervention was purified CBD or every study was randomized. The included designs ranged widely The review identified 23 relevant studies spanning case reports, case…

Spread the love

Read Article: A Psychiatric CBD Review’s Recommendation Grades Included Both CBD and THC-Containing Nabiximols

CBD Eye Research: Molecular Targets and Clinical Ocular Treatment Are Different Evidence Levels

A 2021 ocular CBD review brought together in-vitro and in-vivo research, proposed molecular targets and possible therapeutic applications. This evidence maps a development pathway; it does not establish that CBD products are effective eye treatments. The experimental system belongs in the conclusion A cellular result can identify a target or…

Spread the love

Read Article: CBD Eye Research: Molecular Targets and Clinical Ocular Treatment Are Different Evidence Levels

CBD Addiction Research Measures Reinforcement, Motivation and Withdrawal as Different Outcomes

A 2021 review evaluated CBD research on reinforcing, motivational and withdrawal-related drug effects. These outcomes can inform substance-use-disorder research, but an improvement in one cannot establish successful treatment across all of them. The source combined preclinical and clinical reports The review covered alcohol, opioids, cannabinoids, nicotine and psychostimulants. An animal…

Spread the love

Read Article: CBD Addiction Research Measures Reinforcement, Motivation and Withdrawal as Different Outcomes

Speak with an expert today!

Contact the offices of Okorie Okorocha for professional and reliable advice which you can trust.

Call (424) 363-3347 Contact Us